Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18393471 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5930413 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1469730 | 0.96 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1469731 | 0.96 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1469828 | 0.96 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12747385 | 0.90 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL769352 | 0.90 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1469661 | 0.90 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6690985 | 0.87 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10445844 | 0.86 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | QUADEX PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC | 2015-12-03 | — | — | US | disclosed |
| US-9125911-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | QUADEX PHARMACEUTICALS, LLC | 2006-06-22 | — | — | US | disclosed |
| EP-0464769-B1 | Purinyl and pyrimidinyl tetrahydrofurans | SQUIBB & SONS INC (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5272152-A | Purinyl and pyrimidinyl tetrahydrofurans | E. R. SQUIBB & SONS, INC. (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0464769-A2 | Purinyl and pyrimidinyl tetrahydrofurans | E.R. SQUIBB & SONS, INC. (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | SAMHD1, DCTD, NT5E | SLC28A1 37/4885SLC28A2 39/4885SLC29A1 19/4885 |
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | DCTD, ADA, TYMP | SLC28A1 606/4885SLC28A2 577/4885SLC29A1 48/4885 |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | NT5E, SAMHD1, DCTD | SLC28A1 34/4885SLC28A2 35/4885SLC29A1 23/4885 |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | SAMHD1, CUTA, TK1 | SLC28A1 24/4885SLC28A2 21/4885SLC29A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.